Table 1.
Patient characteristics
| Clinical parameters (n = 561) | |
|---|---|
| Age (years) | 60 ± 11 |
| Sex (male/female) | 44/56 |
| BMI (kg/m2) | 33.4 ± 6.2 |
| Overweight | 26 |
| Obese | 66 |
| Ethnicity | |
| Caucasian | 57 |
| African American | 30 |
| Hispanics | 7 |
| Asian | 4 |
| Other/not reported | 2 |
| HbA1c (%) | 7.5 ± 1.8 |
| Fasting plasma glucose (mg/dL) | 143 ± 61 |
| Systolic blood pressure (mmHg) | 134 ± 16 |
| Diastolic blood pressure (mmHg) | 79 ± 9 |
| Total cholesterol (mg/dL) | 166 ± 49 |
| Triglycerides (mg/dL) | 156 ± 137 |
| LDL cholesterol (mg/dL) | 89 ± 39 |
| HDL cholesterol (mg/dL) | 47 ± 12 |
| AST (units/L) | 21 ± 10 |
| ALT (units/L) | 24 ± 16 |
| Mean CAP (dB/m) | 305 ± 63 |
| Mean LSM (kPa) | 6.2 ± 3.4 |
| Diabetes medications | |
| Metformin | 76 |
| Sulfonylureas | 24 |
| SGLT2 inhibitors | 7 |
| DPP-4 inhibitors | 14 |
| Insulin | 38 |
| Lipid-lowering agents | |
| Statins | 67 |
| Fibrates | 4 |
| Ezetimibe | 1 |
Data are mean ± SE or %.
DPP-4, dipeptidyl peptidase 4; SGLT2, sodium–glucose cotransporter 2.